Changing Paradigms in ITP Management: Newer Tools for an Old Disease

Blanchette, 1998, The history of idiopathic thrombocytopenic purpura (ITP), Transfus Sci, 19, 231, 10.1016/S0955-3886(98)00036-8 Harrington, 1990, Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura. 1951, J Lab Clin Med, 115, 636 Neunert, 2019, American Society of Hematology 2019 guidelines for immune thrombocytopenia, Blood Adv, 3, 3829, 10.1182/bloodadvances.2019000966 Lucchini, 2019, Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019?, Haematologica, 104, 1124, 10.3324/haematol.2019.218883 Nazi, 2013, The effect of rituximab on vaccine responses in patients with immune thrombocytopenia, Blood, 122, 1946, 10.1182/blood-2013-04-494096 Ghanima, 2019, Thrombopoietin receptor agonists: ten years later, Haematologica, 104, 1112, 10.3324/haematol.2018.212845 Deng, 2021, Comparative efficacy and safety of Thrombopoietin receptor agonists in adults with thrombocytopenia: a systematic review and network meta-analysis of randomized controlled trial, Front Pharmacol, 12, 10.3389/fphar.2021.704093 Lok, 1994, Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo, Nature, 369, 565, 10.1038/369565a0 Kuter, 2009, Thrombopoietin and platelet production in chronic immune thrombocytopenia, Hematol Oncol Clin North Am, 23, 1193, 10.1016/j.hoc.2009.09.001 Li, 2001, Thrombocytopenia caused by the development of antibodies to thrombopoietin, Blood, 98, 3241, 10.1182/blood.V98.12.3241 Bussel, 2006, AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP, N Engl J Med, 355, 1672, 10.1056/NEJMoa054626 Mei, 2021, A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia, J Hematol Oncol, 14, 37, 10.1186/s13045-021-01047-9 Kong, 2017, A novel recombinant human thrombopoietin therapy for the management of immune thrombocytopenia in pregnancy, Blood, 130, 1097, 10.1182/blood-2017-01-761262 Provan, 2019, Updated international consensus report on the investigation and management of primary immune thrombocytopenia, Blood Adv, 3, 3780, 10.1182/bloodadvances.2019000812 Jurczak, 2018, Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia, Br J Haematol, 183, 479, 10.1111/bjh.15573 Tarantino, 2020, Efficacy analyses from the immune thrombocytopenia (ITP) clinical development program for avatrombopag: comparisons with placebo and eltrombopag, Blood, 136, 23, 10.1182/blood-2020-142788 Kuter, 2008, Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial, Lancet, 371, 395, 10.1016/S0140-6736(08)60203-2 Cheng, 2011, Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study, Lancet, 377, 393, 10.1016/S0140-6736(10)60959-2 Al-Samkari, 2022, Efficacy and safety evaluation of avatrombopag in immune thrombocytopenia: analyses of a phase III study and long-term extension, Platelets, 33, 257, 10.1080/09537104.2021.1881952 Al-Samkari, 2022, Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study, Br J Haematol, 197, 359, 10.1111/bjh.18081 González-Porras, 2019, Switching thrombopoietin receptor agonist treatments in patients with primary immune thrombocytopenia, Ther Adv Hematol, 10, 10.1177/2040620719837906 Cooper, 2021, Tapering and discontinuation of thrombopoietin receptor agonist therapy in patients with immune thrombocytopenia: results from a modified delphi panel, Acta Haematol, 144, 418, 10.1159/000510676 Poston, 2019, Glucocorticoids promote response to thrombopoietin-receptor agonists in refractory ITP: a case series, Int J Hematol, 110, 255, 10.1007/s12185-019-02638-6 Carpenedo, 2021, Second-line administration of thrombopoietin receptor agonists in immune thrombocytopenia: Italian Delphi-based consensus recommendations, Ther Adv Hematol, 12, 10.1177/20406207211048361 George, 2009, Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials, Br J Haematol, 144, 409, 10.1111/j.1365-2141.2008.07464.x Kuter, 2012, Health-related quality of life in nonsplenectomized immune thrombocytopenia patients receiving romiplostim or medical standard of care, Am J Hematol, 87, 558, 10.1002/ajh.23163 Tremblay, 2018, Cost-consequence model comparing eltrombopag and romiplostim in pediatric patients with chronic immune thrombocytopenia, Clinicoecon Outcomes Res, 10, 715, 10.2147/CEOR.S177338 Bradbury, 2021, Mycophenolate mofetil for first-line treatment of immune thrombocytopenia, N Engl J Med, 385, 885, 10.1056/NEJMoa2100596 Gudbrandsdottir, 2013, Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia, Blood, 121, 1976, 10.1182/blood-2012-09-455691 Zaja, 2010, Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia, Blood, 115, 2755, 10.1182/blood-2009-07-229815 Taylor, 2015, Mycophenolate mofetil therapy for severe immune thrombocytopenia, Br J Haematol, 171, 625, 10.1111/bjh.13622 Hou, 2003, Mycophenolate mofetil (MMF) for the treatment of steroid-resistant idiopathic thrombocytopenic purpura, Eur J Haematol, 70, 353, 10.1034/j.1600-0609.2003.00076.x McMillan, 2008, Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura, Am J Hematol, 83, 150, 10.1002/ajh.20992 Cooper, 2021, Immune thrombocytopenia (ITP) World Impact Survey (I-WISh): impact of ITP on health-related quality of life, Am J Hematol, 96, 199, 10.1002/ajh.26036 Sun, 2021, Dexamethasone plus oseltamivir versus dexamethasone in treatment-naive primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial, Lancet Haematol, 8, e289, 10.1016/S2352-3026(21)00030-2 Huang, 2021, All-trans retinoic acid plus high-dose dexamethasone as first-line treatment for patients with newly diagnosed immune thrombocytopenia: a multicentre, open-label, randomised, controlled, phase 2 trial, Lancet Haematol, 8, e688, 10.1016/S2352-3026(21)00240-4 Bussel, 2018, Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials, Am J Hematol, 93, 921, 10.1002/ajh.25125 Boccia, 2020, Fostamatinib is an effective second-line therapy in patients with immune thrombocytopenia, Br J Haematol, 190, 933, 10.1111/bjh.16959 Deng, 2016, Targeting Syk in autoimmune rheumatic diseases, Front Immunol, 7, 78, 10.3389/fimmu.2016.00078 Langrish, 2021, Preclinical efficacy and anti-inflammatory mechanisms of action of the bruton tyrosine kinase inhibitor rilzabrutinib for immune-mediated disease, J Immunol, 206, 1454, 10.4049/jimmunol.2001130 Kuter, 2022, Rilzabrutinib, an Oral BTK Inhibitor, in immune thrombocytopenia, N Engl J Med, 386, 1421, 10.1056/NEJMoa2110297 Roopenian, 2007, FcRn: the neonatal Fc receptor comes of age, Nat Rev Immunol, 7, 715, 10.1038/nri2155 Newland, 2020, Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia, Am J Hematol, 95, 178, 10.1002/ajh.25680 Robak, 2020, Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia, Blood Adv, 4, 4136, 10.1182/bloodadvances.2020002003 Argenx. https://www.argenx.com/news/argenx-announces-positive-phase-3-data-advance-trial-vyvgartr-efgartigimod-alfa-fcab-adults 2022 August 28th 2022. Mahévas, 2013, B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells, J Clin Invest, 123, 432, 10.1172/JCI65689 Ratnasingam, 2016, Bortezomib-based antibody depletion for refractory autoimmune hematological diseases, Blood Adv, 1, 31, 10.1182/bloodadvances.2016001412 Beckman, 2018, Bortezomib for refractory immune-mediated thrombocytopenia purpura, Am J Ther, 25, e270, 10.1097/MJT.0000000000000517 Peerschke, 2016, Classical complement pathway activation in immune thrombocytopenia purpura: inhibition by a novel C1s inhibitor, Br J Haematol, 173, 942, 10.1111/bjh.13648 Broome, 2019, Inhibition of the classical pathway of complement with Sutimlimab in chronic immune thrombocytopenic purpura patients without adequate response to two or more prior therapies, Blood, 134, 898, 10.1182/blood-2019-122210